For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
A biomarker is, according to the US National Institutes of Health, "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention."
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
Proteomic biomarkers: Base on the analysis of the protein profiles.
Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
Scope of the Report:
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry.
North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%.
The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%.
The worldwide market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 24400 million US$ in 2024, from 17200 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Roche
- Dako (Agilent Technologies)
- Merck
- BD
- Abbott
- Genesys Biolabs (20/20GeneSystems)
- Affymetrix
- Agendia
- ALMAC
- Arrayit
- Biocartic
- BG Medicine
- KEGG EXPRESSION Database
- Thermo Fisher
- BGI
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Consumables
- Services
- Software
Market Segment by Applications, can be divided into
- Oncology
- Cardiology
- Neurology
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Commercializing Biomarkers in Therapeutic and Diagnostic Applications product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with price, sales, revenue and global market share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in 2017 and 2018.
Chapter 3, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Commercializing Biomarkers in Therapeutic and Diagnostic Applications market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales channel, distributors, customers, research findings and conclusion, appendix and data source.